Open AccessTransient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report
Author(s) -
Jawad Majd D.,
Go Ronald S.,
Ketterling Rhett P.,
Begna Kebede H.,
Reichard Kaaren K.,
Shi Min
Publication year - 2016
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.506
Subject(s) - nilotinib , medicine , chronic myelogenous leukemia , monosomy , myeloid leukemia , cancer research , philadelphia chromosome , tyrosine kinase inhibitor , oncology , dasatinib , tyrosine kinase , aneuploidy , imatinib , leukemia , chromosome , karyotype , chromosomal translocation , genetics , biology , cancer , receptor , gene
Key Clinical Message Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph−) cells tend to evolve into MDS / AML . However, monosomy 7 in Ph− cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.